{"Clinical Trial ID": "NCT00558272", "Intervention": ["INTERVENTION 1:", "AZD0530 175 mg", "AZD0530 (saracatinib) 175 mg once daily", "INTERVENTION 2:", "zoledronic acid 4 mg", "zoledronic acid 4 mg on day 1 of the 4 week treatment period"], "Eligibility": ["Incorporation criteria:", "Subjects 18 years of age or older with prostate cancer or breast cancer with metastatic bone disease", "At least one metastatic bone injury confirmed by X-ray", "No change in cancer treatment for at least 8 weeks prior to randomisation", "- Exclusion criteria:", "Have already been exposed to bisphosphonate", "Have had hip fractures or bilateral hip prosthesis fractures of any kind or bone surgery in the last 12 months", "Insufficiency of renal function or low haemoglobin", "Inadequate hepatic function demonstrated by serum bilirubin twice the upper limits of the reference range (ULRR) or by alanine aminotransferase (ALT), aspartate aminotransferase (AST) or ALP 2.5 times ULRR ( 5 times ULRR in the presence of liver metastases)."], "Results": ["Performance measures:", "- Rate of change from baseline in beta-terminal type I cross-link telopeptide (betaCTX) at week 4", "Result at week 4 minus result at the base as a percentage of the result at the base, based on converted log data.", "Calendar: Baseline at week 4", "Results 1:", "Title of arm/group: AZD0530 175 mg", "Description of the arm/group: AZD0530 (saracatinib) 175 mg once daily", "Total number of participants analysed: 46", "Geometric mean (95% confidence interval)", "Unit of measure: Percentage change in betaCTX -71.1 (-75.9 to -65.4)", "Results 2:", "Title of arm/group: Zoledronic acid 4 mg", "Description of the arm/group: Zoledronic acid 4 mg on day 1 of the 4 week treatment period", "Total number of participants analysed: 65", "Geometric mean (95% confidence interval)", "Unit of measure: Percentage change in betaCTX -68.4 (-73.0 to -63.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 11/68 (16.18 per cent)", "Anemia 1/68 (1.47%)", "1/68 (1.47%)", "Myocardial infarction 1/68 (1.47%)", "Vomiting 1/68 (1.47%)", "General deterioration of physical health 0/68 (0.00 %)", "Pyrexia 1/68 (1.47%)", "Pneumonia 2/68 (2.94%)", "Viral infection 1/68 (1.47%)", "Increased blood creatinine 0/68 (0.00 %)", "Dehydration 0/68 (0.00 %)", "Bone pain 0/68 (0.00 %)", "Adverse Events 2:", "Total: 4/69 (5.80 per cent)", "Anemia 0/69 (0.00 %)", "- Cardiac arrest 0/69 (0.00 %)", "Myocardial infarction 0/69 (0.00 %)", "Vomiting 0/69 (0.00 %)", "General deterioration of physical health 1/69 (1.45%)", "Pyrexia 0/69 (0.00 %)", "Pneumonia 0/69 (0.00 %)", "- Viral infection 0/69 (0.00 %)", "Increased blood creatinine 1/69 (1.45%)", "Dehydration 1/69 (1.45%)", "Bone pain 1/69 (1.45%)"]}